Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
Primary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-09-01
|
| Series: | CNS Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0021 |
| _version_ | 1826992241467457536 |
|---|---|
| author | Andy Liu Huda Alalami Xuemo Fan Chirag Patil Jaya M Gill Santosh Kesari Jethro Hu |
| author_facet | Andy Liu Huda Alalami Xuemo Fan Chirag Patil Jaya M Gill Santosh Kesari Jethro Hu |
| author_sort | Andy Liu |
| collection | DOAJ |
| description | Primary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious, treatment options for MTX-refractory disease are not well-defined. Here, we report a case of a 38-year-old man with refractory primary T-cell CNS lymphoma who demonstrated a complete response to pemetrexed treatment. He subsequently received conditioning chemotherapy consisting of thiotepa, busulfan and cyclophosphamide followed by autologous stem cell transplantation. The patient continues to remain recurrence-free to date at 9 years post-treatment. |
| first_indexed | 2024-03-12T16:59:58Z |
| format | Article |
| id | doaj.art-93a81df1dd514b00bdd8edb40751e370 |
| institution | Directory Open Access Journal |
| issn | 2045-0907 2045-0915 |
| language | English |
| last_indexed | 2025-02-18T08:46:52Z |
| publishDate | 2023-09-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | CNS Oncology |
| spelling | doaj.art-93a81df1dd514b00bdd8edb40751e3702024-11-02T23:58:12ZengTaylor & Francis GroupCNS Oncology2045-09072045-09152023-09-0112310.2217/cns-2022-0021Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNSAndy Liu0Huda Alalami1Xuemo Fan2Chirag Patil3Jaya M Gill4Santosh Kesari5Jethro Hu61Pacific Neuroscience Institute & Saint John's Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA2Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA2Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA2Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA1Pacific Neuroscience Institute & Saint John's Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA1Pacific Neuroscience Institute & Saint John's Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA2Cedars-Sinai Medical Center, Los Angeles, CA 90048, USAPrimary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious, treatment options for MTX-refractory disease are not well-defined. Here, we report a case of a 38-year-old man with refractory primary T-cell CNS lymphoma who demonstrated a complete response to pemetrexed treatment. He subsequently received conditioning chemotherapy consisting of thiotepa, busulfan and cyclophosphamide followed by autologous stem cell transplantation. The patient continues to remain recurrence-free to date at 9 years post-treatment.https://www.futuremedicine.com/doi/10.2217/cns-2022-0021case reportPCNSLpemetrexedT cellT-cell lymphoma |
| spellingShingle | Andy Liu Huda Alalami Xuemo Fan Chirag Patil Jaya M Gill Santosh Kesari Jethro Hu Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS CNS Oncology case report PCNSL pemetrexed T cell T-cell lymphoma |
| title | Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS |
| title_full | Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS |
| title_fullStr | Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS |
| title_full_unstemmed | Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS |
| title_short | Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS |
| title_sort | long term survival after salvage pemetrexed for refractory primary t cell lymphoma of the cns |
| topic | case report PCNSL pemetrexed T cell T-cell lymphoma |
| url | https://www.futuremedicine.com/doi/10.2217/cns-2022-0021 |
| work_keys_str_mv | AT andyliu longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns AT hudaalalami longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns AT xuemofan longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns AT chiragpatil longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns AT jayamgill longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns AT santoshkesari longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns AT jethrohu longtermsurvivalaftersalvagepemetrexedforrefractoryprimarytcelllymphomaofthecns |